News & Videos - ZOMEDICA CORP. - Page 2

ANN ARBOR, Mich., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that, with the hiring of Debra Rock to lead the Company’s Marketing Department, its internal commercial leadership team is complete. Joining Zomedica as Senior Director of Downstream Marketing & Communications is Debra Rock. Ms. Rock is an experienced marketing...

ANN ARBOR, Mich., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, today announced that it expects to begin commercialization of its TRUFORMA™ point-of-care diagnostic platform on March 30, 2021. Protected by approximately 70 issued and pending patents, the TRUFORMA platform uses Bulk Acoustic Wave (“BAW”) technology, developed by Qorvo...

ANN ARBOR, Mich., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or “Company”) today reported consolidated financial results for the third quarter ended September 30, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”). Summary Third Quarter 2020 Results Zomedica recorded net loss and comprehensive loss for the three and...

ANN ARBOR, Mich., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) announced today that the following letter from Robert Cohen, Interim Chief Executive Officer, has been made available to shareholders. Dear Shareholders: I am writing to you today with a single, straightforward message -- please vote for the domestication proposal described in our proxy materials for our virtual Special Meeting to be held on December 15, 2020. Approval of the domestication proposal will...

ANN ARBOR, Mich., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. (formerly Zomedica Pharmaceuticals Corp.) (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostic products for companion animals, announced that it has changed its legal name to Zomedica Corp. The Company’s stock trading symbol will remain as ZOM on the NYSE American and the shares will begin trading under the new name effective on October 5, 2020. The...

ANN ARBOR, Mich., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for companion animals, today announced the voting results of its 2020 Annual and Special Virtual-Only Meeting of Shareholders (the “ Meeting”). At the Meeting, the Company’s shareholders approved the following proposals: Election of Jeffrey Rowe, Robert Cohen, Johnny D. Powers,...

ANN ARBOR, Mich., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that its proxy solicitor, Alliance Advisors, mailed the following letter to selected shareholders in advance of its Annual and Special Virtual-Only Meeting of Shareholders to be held on September 25, 2020. Dear Zomedica Pharmaceuticals Corp. Shareholder: Our records reflect that you have not yet voted your shares with respect to Proposal 3 to be acted upon at the Annual and...

ANN ARBOR, Mich., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), a veterinary health company creating point-of-care diagnostics products for companion animals, announced today that Robert Cohen, Interim Chief Executive Officer, and Stephanie Morley, President and Chief Medical Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference. The presentation is scheduled for September 14, 2020 at 4:00 pm ET. The slides to be...

ANN ARBOR, Mich., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that it has agreed with its development partner Qorvo Biotechnologies, LLC, a wholly owned subsidiary of Qorvo US, Inc., to develop three new assays -- Cobalamin, cPL (canine Pancreatic Lipase), and Folate -- to target diagnosis of canine gastrointestinal issues. The new assays are in addition to the initial five assays currently under development, including panels for adrenal...

ANN ARBOR, Mich., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced today that the following letter from Robert Cohen, Interim Chief Executive Officer, has been made available to shareholders. Dear Zomedica Shareholders: As I pass my second month anniversary at Zomedica, I have been looking forward to communicating with you directly and to offering both my impressions of the Company and an update on our progress. I am pleased to report that I have...

ANN ARBOR, Mich., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (“Zomedica” or “Company”), a veterinary health company, today reported consolidated financial results for the second quarter ended June 30, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America (“U.S. GAAP”). “During the last several months, Zomedica successfully managed...

ANN ARBOR, Mich., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (“Zomedica”) (NYSE American: ZOM), a veterinary health company, announced that Robert Cohen, Interim Chief Executive Officer, has been appointed to the Company's Board of Directors. Also appointed to the Board of Directors is Christopher Wolfenberg of the law firm Fasken Martineau DuMoulin LLP. Mr. Cohen joined Zomedica in June of 2020 following successfully serving as President and Chief Executive Officer at...

ANN ARBOR, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (“Zomedica”) (NYSE American: ZOM) (TSX-V: ZOM), a veterinary health company, announced that Shameze Rampertab has resigned as Chief Financial Officer and member of the Board of Directors, effective August 14, 2020. Ann Cotter, CPA, will act as interim CFO. Ms. Cotter has served as the Vice President of Finance for Zomedica from August of 2018, where she has taken a lead role in the internal accounting...

ANN ARBOR, Mich., July 21, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary health company, announced today that, in response to the COVID-19 crisis, it successfully implemented its first completely remote installations of TRUFORMA™, the Company's inaugural point-of-care diagnostic device. Remote installation has enabled Zomedica to proceed with validation testing with its clinical College of Veterinary Medicine...

ANN ARBOR, Mich., July 07, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the closing of its previously announced public offering of 187,500,000 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 187,500,000 common shares, at a combined public offering price of $0.16 per share and accompanying warrant. H.C. Wainwright & Co. acted...

ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of its previously announced public offering of 187,500,000 common shares (or common share equivalents) of the Company, together with short-term warrants to purchase up to 187,500,000 common shares, at a combined public offering price of $0.16 per share and accompanying warrant. Each common...

ANN ARBOR, Mich., July 01, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM), (“Zomedica” or the “Company”), a veterinary diagnostic company, announced today that it has commenced a public offering of its common shares, together with warrants to purchase its common shares. All of the common shares and warrants in the offering will be sold by Zomedica. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering...

ANN ARBOR, Mich., June 16, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (“Zomedica” or the “Company”) (NYSE American: ZOM), a veterinary diagnostic company, announced that it has appointed Robert Cohen, formerly of EmboMedics, Inc., as its Interim Chief Executive Officer, effective immediately. Mr. Cohen brings to Zomedica more than 15 years executive leadership and operations experience from the medical device market, and biotechnology and pharmaceutical industries. Mr. Cohen...

ANN ARBOR, Mich., May 29, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the closing of its previously announced public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, at a combined public offering price of $0.15 per share and accompanying warrant. H.C. Wainwright & Co. acted...

ANN ARBOR, Mich., May 26, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary diagnostic company, today announced the pricing of a public offering of 133,333,333 common shares (or common share equivalents) of the Company, together with warrants to purchase up to 133,333,333 common shares, at a combined public offering price of $0.15 per share and accompanying warrant. Each common share (or common share equivalent) is...